Refractory T-Cell Non-Hodgkin Lymphoma

MedGen UID:: 163468
•Concept ID:: C0854827
•: Neoplastic Process

Synonyms:

Refractory T-Cell and NK-Cell Non-Hodgkin's Lymphoma; Refractory T-Cell Lymphoma; Refractory T-Cell Non-Hodgkin's Lymphoma; T-Cell Lymphoma Refractory

Definition

T-cell non-Hodgkin lymphoma resistant to treatment. [from NCI]

Term Hierarchy

GTR
MeSH

CClinical test, RResearch test, OOMIM, GGeneReviews, VClinVar

CROGVRefractory T-Cell Non-Hodgkin Lymphoma

Hematopoietic and Lymphoid System Disorder
- Hematologic disorder
  - Hematologic neoplasm
    - Lymphoma
      - Non-Hodgkin lymphoma
        Refractory Non-Hodgkin Lymphoma
        Refractory T-Cell Non-Hodgkin Lymphoma
        Refractory Aggressive T-Cell Non-Hodgkin Lymphoma
        Refractory Adult T-Cell Leukemia/Lymphoma
        Refractory Angioimmunoblastic T-Cell Lymphoma
        Refractory Breast Implant-Associated Anaplastic Large Cell Lymphoma
        Refractory Enteropathy-Associated T-Cell Lymphoma
        Refractory Hepatosplenic T-Cell Lymphoma
        Refractory Monomorphic Epitheliotropic Intestinal T-cell Lymphoma
        Refractory Nasal Type Extranodal NK/T-Cell Lymphoma
        Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified
        Refractory T Lymphoblastic Lymphoma
        Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
        Refractory Anaplastic Large Cell Lymphoma
        Refractory Primary Cutaneous Anaplastic Large Cell Lymphoma
        Refractory Systemic Anaplastic Large Cell Lymphoma
        Refractory Follicular T-Cell Lymphoma
        Refractory Mycosis Fungoides and Sezary Syndrome
        Refractory Mycosis Fungoides
        Refractory Sezary Syndrome
        Refractory NK-Cell Lymphoma, Unclassifiable
        Refractory Nodal Peripheral T-Cell Lymphoma with TFH Phenotype
        Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
        Refractory Subcutaneous Panniculitis-Like T-Cell Lymphoma
        Refractory Transformed T-cell Non-Hodgkin Lymphoma
        Refractory Transformed Mycosis Fungoides

Professional guidelines

PubMed

Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment.

Bock AM, Nowakowski GS, Wang Y
Curr Treat Options Oncol 2022 Feb;23(2):155-170. Epub 2022 Feb 19 doi: 10.1007/s11864-021-00925-1. PMID: 35182296

Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA).

Hayden PJ, Roddie C, Bader P, Basak GW, Bonig H, Bonini C, Chabannon C, Ciceri F, Corbacioglu S, Ellard R, Sanchez-Guijo F, Jäger U, Hildebrandt M, Hudecek M, Kersten MJ, Köhl U, Kuball J, Mielke S, Mohty M, Murray J, Nagler A, Rees J, Rioufol C, Saccardi R, Snowden JA, Styczynski J, Subklewe M, Thieblemont C, Topp M, Ispizua ÁU, Chen D, Vrhovac R, Gribben JG, Kröger N, Einsele H, Yakoub-Agha I
Ann Oncol 2022 Mar;33(3):259-275. Epub 2021 Dec 16 doi: 10.1016/j.annonc.2021.12.003. PMID: 34923107

European Society for the Study of Coeliac Disease (ESsCD) guideline for coeliac disease and other gluten-related disorders.

Al-Toma A, Volta U, Auricchio R, Castillejo G, Sanders DS, Cellier C, Mulder CJ, Lundin KEA
United European Gastroenterol J 2019 Jun;7(5):583-613. Epub 2019 Apr 13 doi: 10.1177/2050640619844125. PMID: 31210940 Free PMC Article

See all (371)

Recent clinical studies

Etiology

Imatinib mesylate lacks efficacy in relapsed/refractory peripheral T cell lymphoma.

Jacobsen E, Pozdnyakova O, Redd R, Fisher DC, Dorfman DM, Dal Cin P, LaCasce A, Armand P, Hochberg E, Cote G, Shahsafaei A, Neuberg D, Brown JR, Freedman AS
Leuk Lymphoma 2015 Apr;56(4):993-8. Epub 2014 Aug 20 doi: 10.3109/10428194.2014.941835. PMID: 25012943

See all (1)

Therapy

Severe Generalized Weakness, Paraplegia following administration of Oxaliplatin in a patient with refractory T-cell non-Hodgkin lymphoma: A case report.

Zarei B, Moeini Nodeh M, Arasteh O
J Oncol Pharm Pract 2022 Jun;28(4):1009-1013. Epub 2022 Jan 10 doi: 10.1177/10781552211073531. PMID: 35006005

Imatinib mesylate lacks efficacy in relapsed/refractory peripheral T cell lymphoma.

Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma.

Dang NH, Pro B, Hagemeister FB, Samaniego F, Jones D, Samuels BI, Rodriguez MA, Goy A, Romaguera JE, McLaughlin P, Tong AT, Turturro F, Walker PL, Fayad L
Br J Haematol 2007 Feb;136(3):439-47. doi: 10.1111/j.1365-2141.2006.06457.x. PMID: 17233846

Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies.

Orlowski RZ, Voorhees PM, Garcia RA, Hall MD, Kudrik FJ, Allred T, Johri AR, Jones PE, Ivanova A, Van Deventer HW, Gabriel DA, Shea TC, Mitchell BS, Adams J, Esseltine DL, Trehu EG, Green M, Lehman MJ, Natoli S, Collins JM, Lindley CM, Dees EC
Blood 2005 Apr 15;105(8):3058-65. Epub 2004 Dec 30 doi: 10.1182/blood-2004-07-2911. PMID: 15626743

See all (4)